SynthesisNeuroradiology2026
Efficacy and safety of intravenous nerinetide in acute ischemic stroke patients undergoing endovascular thrombectomy without thrombolysis: a meta-analysis of randomized controlled trials.
Synthesis in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis systematic review and meta-analysis aimed to evaluate the safety and efficacy of intravenous (IV) nerinetide in acute ischemic stroke (AIS) patients undergoing endovascular thrombectomy (EVT) without prior or concurrent IV thrombolysis (IVT).
methodsA systematic search of PubMed, Web of Science, and Scopus was conducted through March 15, 2025, identifying randomized controlled trials (RCTs) comparing EVT plus nerinetide versus EVT plus placebo without IVT. Screening and data extraction were performed independently by two reviewers, with conflicts resolved by a third. Risk of bias was assessed using RoB 2.0. Data were synthesized using RevMan 5.4 with random-effects models, and heterogeneity was evaluated via chi-square and I
resultsThree RCTs comprising 726 patients in the IV nerinetide group and 668 in the placebo group were included. Nerinetide did not significantly improve functional outcomes: 90-day modified Rankin Scale (mRS) 0-1 (RR: 1.02, 95% CI: [0.71, 1.47], P = 0.92) and mRS 0-2 (RR: 1.07, 95% CI: [0.93, 1.22], P = 0.35). No significant differences were observed in 90-day mortality (RR: 0.89, 95% CI: [0.60, 1.34], P = 0.59) or adverse events, including symptomatic intracranial hemorrhage (RR: 0.80, 95% CI: [0.44, 1.45], P = 0.46).
conclusionNerinetide administration during EVT in AIS patients without IVT did not significantly improve functional independence, survival, or safety outcomes compared to placebo. Although preclinical data supported neuroprotection, clinical benefits were not observed, highlighting the challenges in translating neuroprotective strategies into effective stroke therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.